下一代测序研究确定了孟加拉国人口中与阿尔茨海默病相关的第一个基因:CARED研究
Maliha Hakim1, Redoy Ranjan2,3, Gie Ken-Dror2
1Department of Neurology, National Institute of Neurosciences and Hospital, Dhaka, Bangladesh.
Journal of Alzheimer's disease : JAD
|February 24, 2026
概括
在孟加拉国人口中,Apolipoprotein E (APOE) 变体rs429358显著增加了阿尔茨海默氏症的风险8倍. 这一遗传发现突显了APOE在阿尔茨海默氏症中的重要性.
科学领域:
- 遗传学 是一个遗传学.
- 神经科学是一个神经科学.
- 人口健康 人口健康
背景情况:
- 阿尔茨海默病 (AD) 遗传研究主要集中在高加索人群中.
- 孟加拉国人的AD遗传基础在很大程度上仍未被探索.
研究的目的:
- 调查Apolipoprotein E (APOE) 和其他基因中单核酸变体 (SNV) 与孟加拉国阿尔茨海默病风险之间的关联.
- 在南亚人群中确定导致AD易受影响的遗传因素.
主要方法:
- 从孟加拉国招募阿尔茨海默病患者和年龄/性别匹配的对照 (n=132).
- 下一代测序 (NGS) 来分析外体和线粒体基因组.
- 包括Bonferroni调整在内的统计分析,以确定重要的SNV.
主要成果:
- Apolipoprotein E (APOE) 变体rs429358显示出与AD风险增加的显著关联 (OR 8.0,p=0.001).
- 这种APOE变异是阿尔茨海默病的首要预测因素,其次是BDNF和CR1基因的变异.
- 在AD患者和对照人群之间没有观察到年龄或性别分布的显著差异.
结论:
- APOE变种rs429358与孟加拉国人口中阿尔茨海默病风险增加密切相关.
- 这一发现强调了APOE基因在多种种族群体的AD病原体中的作用.
- 在代表性不足的人群中对AD遗传学的进一步研究是有必要的.
更多相关视频
04:41Mapping Alzheimer's Disease Variants to Their Target Genes Using Computational Analysis of Chromatin Configuration
Published on: January 9, 2020
19.5K
07:26High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
Published on: July 18, 2017
12.3K
相关概念视频
01:11Genome-wide Association Studies-GWAS
15.9K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
15.9K
01:26Alzheimer's Disease: Overview
1.9K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K
01:22Alzheimer's Disease: Treatment
1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
03:00Next-generation Sequencing
99.4K
The first human genome sequencing project cost $2.7 billion and was declared complete in 2003, after 15 years of international cooperation and collaboration between several research teams and funding agencies. Today, with the advent of next-generation sequencing technologies, the cost and time of sequencing a human genome have dropped over 100 fold.
Next-Generation Sequencing Methods
Although all next-generation methods use different technologies, they all share a set of standard features....
Next-Generation Sequencing Methods
Although all next-generation methods use different technologies, they all share a set of standard features....
99.4K
01:29Pharmacogenomics: Identification of New Drug Targets
49
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
49